Human ECM for oncology research
.png)
Our human-derived ECM (hECM) for oncology is designed to faithfully replicate the tumor microenvironment, providing a physiologically relevant matrix for cancer research, drug development, and tumor modeling. Produced from human oncological tissues through a proprietary decellularization process, this ECM preserves essential biochemical cues, including native growth factors and structural proteins, that drive cancer cell proliferation, invasion, and therapeutic resistance.
Leveraging the bioactivity of our hECM, researchers can generate self-assembled organoids directly within the matrix, eliminating the need for artificial scaffolds and achieving more predictive tumor models. This approach supports the formation of complex, multicellular structures that closely mimic in vivo tumor architecture and behavior.
To further enhance translational relevance, we offer a selection of isogenic hECM options matched to specific cancer types and genetic backgrounds, enabling precise modeling of disease-specific microenvironments. Whether used for high-content drug screening or studying tumor progression mechanisms, our hECM provides the critical components necessary to advance oncology research and accelerate the discovery of more effective therapies.
